Compare SJM & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SJM | MDGL |
|---|---|---|
| Founded | 1897 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 12.8B |
| IPO Year | 1994 | 2005 |
| Metric | SJM | MDGL |
|---|---|---|
| Price | $122.72 | $524.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | $115.85 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 1.3M | 200.5K |
| Earning Date | 06-09-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | ★ 88.76 | N/A |
| EPS | ★ 3.03 | N/A |
| Revenue | ★ $9,050,900,000.00 | $180,133,000.00 |
| Revenue This Year | $4.71 | $58.39 |
| Revenue Next Year | $1.39 | $48.55 |
| P/E Ratio | $40.17 | ★ N/A |
| Revenue Growth | ★ 3.72 | N/A |
| 52 Week Low | $88.25 | $393.61 |
| 52 Week High | $135.89 | $615.00 |
| Indicator | SJM | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 46.55 |
| Support Level | $115.73 | $499.26 |
| Resistance Level | $127.65 | $546.29 |
| Average True Range (ATR) | 3.32 | 18.41 |
| MACD | -1.30 | -1.00 |
| Stochastic Oscillator | 13.21 | 35.38 |
J.M. Smucker is a packaged food company that primarily sells through the US retail channel (75% of fiscal 2026 revenue came through its retail pet foods, coffee, and frozen handheld/spreads segments), with the remaining share consisting of sweet baked snacks (through the Hostess acquisition), away from home, and international (primarily Canada). Retail coffee is its largest category (37% of sales) with brands Folgers, Dunkin', and Cafe Bustelo. Pet foods (18% of sales) holds leading brands like Milk-Bone and Meow Mix. Of its remaining, approximately 20% comes from frozen handhelds and spreads, through brands Jif, Smucker's, and Uncrustables. The company acquired Hostess Brands in fiscal 2024 to boost its snack and convenience store presence.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.